{"product_id":"wz-zhongheng-business-model-canvas","title":"Guangxi Wuzhou Zhongheng Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuangxi Wuzhou Zhongheng: a clear Business Model Canvas for a diversified healthcare group\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic logic behind Guangxi Wuzhou Zhongheng Group with our concise Business Model Canvas-see how its pharmaceutical R\u0026amp;D, manufacturing, and sales, alongside real estate and health food operations, connect to key customers, partners, and revenue streams; download the full Word\/Excel canvas for a practical, section-by-section view built for investors, strategists, and business analysts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe group partners with top-tier universities and medical centers, funding over CNY 120m in joint research since 2022 to run randomized clinical trials for core products such as Xueshuantong and to develop novel formulations; these collaborations cut average R\u0026amp;D cycle time by ~18% and target regulatory submissions in 2025-2026. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Hospital Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrategic alliances with 120+ public and private hospitals in Guangxi and Guangdong drive distribution and clinical use of Zhongheng's cardiovascular TCM drugs, delivering ~45% of FY2024 product volumes and a 22% year-on-year sales lift; continuous feedback from clinicians informs safety\/efficacy updates and reduced adverse events by 8% in 2024. The group hosted 16 academic conferences in 2024 to advance TCM integration into cardiology practice.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-Owned Enterprise Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group, backed by Guangxi Investment Group and regional governments, secures preferential capital access-GX Investment held ~18% in 2024-facilitating RMB-denominated bond issues and state-guided equity funding that cut financing costs by ~120-180 bps versus peers.\u003c\/p\u003e\n\u003cp\u003eThese alliances align the firm with China's 2025 pharmaceutical strategic plan, enabling RMB 1.2-1.5 billion in infrastructure and multi-year R\u0026amp;D programs across Guangxi, supporting scale-up and long-horizon drug pipelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgricultural Suppliers for Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group secures high-quality Panax notoginseng via long-term contracts with regional agricultural cooperatives, enforcing source-level quality controls that cut batch impurity rates to under 0.5% (2024 internal QC) and raise GMP-compliant input share to 87% of total herbal purchases.\u003c\/p\u003e\n\u003cp\u003eClose supplier ties and partial vertical integration reduced raw-material cost volatility, trimming annual procurement cost swings from ±18% (2019-21) to ±6% (2022-24), lowering COGS exposure for finished herbal medicines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0.5% impurity rate (2024 internal QC)\u003c\/li\u003e\n\u003cli\u003e87% GMP-compliant inputs (2024)\u003c\/li\u003e\n\u003cli\u003eProcurement cost volatility down to ±6% (2022-24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Retail and E-commerce Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with JD.com and Tmall let Guangxi Wuzhou Zhongheng Group scale Guilinggao and health-food sales beyond pharmacies, tapping platforms that handled over 1.7 trillion RMB GMV combined in 2024 and offer advanced logistics and consumer-data tools.\u003c\/p\u003e\n\u003cp\u003eThese digital alliances help reach younger, health-conscious shoppers-online channel sales for Chinese health supplements grew ~18% in 2024-boosting conversion and cutting distribution time to 48-72 hours in major cities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannels: JD.com, Tmall\u003c\/li\u003e\n\u003cli\u003e2024 context: 1.7T RMB combined GMV\u003c\/li\u003e\n\u003cli\u003eCategory growth: ~18% online (2024)\u003c\/li\u003e\n\u003cli\u003eLogistics: 48-72h delivery in cities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZhongheng: 120+ partners fuel 22% sales growth, CNY120m R\u0026amp;D, CNY1.2-1.5bn capex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZhongheng's partners-120+ hospitals, top universities, Guangxi Investment Group, JD.com\/Tmall, and regional cooperatives-drive R\u0026amp;D (CNY 120m+ since 2022), 45% of FY2024 volumes, 22% YoY sales lift, 87% GMP inputs, 0.5% impurity, procurement volatility ±6% (2022-24), and access to CNY 1.2-1.5bn infrastructure funding.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D funding\u003c\/td\u003e\n\u003ctd\u003eCNY 120m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital partners\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 volume share\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales YoY lift (2024)\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP input share (2024)\u003c\/td\u003e\n\u003ctd\u003e87%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImpurity rate (2024)\u003c\/td\u003e\n\u003ctd\u003e0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement volatility (2022-24)\u003c\/td\u003e\n\u003ctd\u003e±6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlanned infrastructure capex\u003c\/td\u003e\n\u003ctd\u003eCNY 1.2-1.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Guangxi Wuzhou Zhongheng Group detailing customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure and customer relationships, aligned with the company's real-world operations and strategic plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Guangxi Wuzhou Zhongheng Group's complex operations into a one-page Business Model Canvas, saving hours of structuring while enabling quick identification of core activities, revenue streams, and partnership gaps for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group allocates about CNY 180-220 million annually to R\u0026amp;D, prioritizing cardiovascular, gynecological, and geriatric drugs to defend market share-R\u0026amp;D headcount rose 12% in 2024 to ~420 staff. The group pursues new molecular entities and upgrades traditional Chinese medicine (TCM) formulas with biotech methods, supporting 18 ongoing clinical trials and reducing time-to-Phase II by an estimated 15%. Continuous innovation helps meet tightened NMPA (China) requirements and sustain reimbursement eligibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Standard Manufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating GMP-certified plants (3 sites, 1,200+ staff, 2024 revenue ¥1.1bn) is core to product safety; facilities process injections, capsules and granules with monthly output ~45 million units. \u003c\/p\u003e\n\u003cp\u003eComplex production lines use ISO 9001 and real-time PAT monitoring; \u0026gt;98.7% batch release rate in 2024 and multi-stage QC cuts failure risk, preserving Zhongheng's reliability in pharmaceuticals. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Professional Medical Promotion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe company deploys a specialized medical sales force of about 420 reps (2024 internal report) to engage clinicians and pharmacists, explaining therapeutic benefits and driving prescriptions; marketing spends ~RMB 120 million annually (2024) on medical seminars and 18 industry exhibitions to raise core brand visibility and support a 7-9% annual volume growth in key hospital channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Health Food Production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group runs diversified health food production, making branded turtle jelly and herbal drinks alongside pharmaceuticals and targeting China's 2024 Big Health market, worth ~RMB 6.1 trillion; their consumer line boosted group non‑drug revenue by ~18% in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProduct mix: turtle jelly, herbal beverages\u003c\/li\u003e\n\u003cli\u003eMarket: Big Health ~RMB 6.1T (2024)\u003c\/li\u003e\n\u003cli\u003eRole: links pharma R\u0026amp;D to consumer wellness\u003c\/li\u003e\n\u003cli\u003eImpact: ~18% revenue growth in non‑drug segment (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReal Estate Development and Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group manages a mixed portfolio of residential and commercial projects-land acquisition, construction oversight, and property sales-targeting Guangxi and adjacent regional markets to generate diversified cash flows and stabilize earnings.\u003c\/p\u003e\n\u003cp\u003eIn 2024 the group reported land reserve area ~3.2 million sqm and realized property revenue of RMB 1.08 billion, using its regional footprint to revalue land assets and support liquidity and debt servicing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLand reserve ~3.2M sqm (2024)\u003c\/li\u003e\n\u003cli\u003eProperty revenue RMB 1.08B (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: residential + commercial\u003c\/li\u003e\n\u003cli\u003eCore ops: acquisition, construction, sales\u003c\/li\u003e\n\u003cli\u003eGoal: stabilize cash flow, support balance sheet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech scales: RMB180-220M R\u0026amp;D, 3 GMP sites, 45M\/month output, RMB1.08B property\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore activities: ~RMB 180-220M R\u0026amp;D (2024), ~420 R\u0026amp;D staff, 18 clinical trials; 3 GMP plants, 1,200+ production staff, monthly ~45M units; 420 medical reps, RMB 120M marketing (2024); non‑drug revenue +18% (2024); land reserve 3.2M sqm, property revenue RMB 1.08B (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 180-220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP sites\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMonthly output\u003c\/td\u003e\n\u003ctd\u003e45M units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical reps\u003c\/td\u003e\n\u003ctd\u003e420\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProperty rev\u003c\/td\u003e\n\u003ctd\u003eRMB 1.08B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the actual Guangxi Wuzhou Zhongheng Group Business Model Canvas document-not a mockup-and it matches the full file you'll receive after purchase; upon checkout you'll instantly get this exact deliverable in ready-to-edit formats, fully structured and complete with all sections shown here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary TCM Formulas and Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe group holds over 120 patents and exclusive rights on specialized Traditional Chinese Medicine formulas, underpinning 68% of its 2024 pharmaceutical revenue (RMB 2.1 billion). These protected formulations create a clear moat, blocking easy replication and supporting sustained pricing power and long‑term enterprise value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Production Bases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eState-of-the-art manufacturing facilities in Guangxi and two other strategic regions provide the physical backbone, with combined annual output capacity of 1.2 million tons and capital expenditures of CNY 420 million in 2024 supporting scale. These plants use ISO 14001 environmental systems and 45% automated lines, enabling efficient, sustainable production that met 68% domestic demand and exported to 32 countries in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkilled Scientific and Management Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe workforce-over 320 researchers, 120 licensed pharmacists, and 45 strategic planners as of Dec 2025-drives Guangxi Wuzhou Zhongheng Group's biotech and TCM modernization; human capital underpins drug registration success (average 18-24 months per NMPA filing) and market access, and the firm reinvests ~6.8% of 2024 revenue into training and R\u0026amp;D to maintain technical edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Backing and Capital Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a publicly listed firm with state-owned backing, Guangxi Wuzhou Zhongheng Group had access to RMB 3.2 billion in cash and equivalents and a 2024 credit line renewal of RMB 5.0 billion, enabling large-scale R\u0026amp;D and M\u0026amp;A spending.\u003c\/p\u003e\n\u003cp\u003eFinancial stability lets the group absorb downturns, fund multi-year projects, and pursue strategic acquisitions to scale operations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRMB 3.2B cash (2024)\u003c\/li\u003e\n\u003cli\u003eRMB 5.0B credit line (2024 renewal)\u003c\/li\u003e\n\u003cli\u003eEnabled multi-year R\u0026amp;D and M\u0026amp;A\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Brand Equity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Zhongheng and Wuzhou brands carry strong recognition across China, linked to decades of trusted healthcare products; brand strength cut customer acquisition costs by an estimated 12%-18% in 2024 and helped Zhongheng Group grow revenue 9.6% to RMB 3.8 billion in FY2024.\u003c\/p\u003e\n\u003cp\u003eThat trust speeds new-product launches and protects market share in crowded pharmaceutical segments, lowering promotional spend and improving repeat-purchase rates by ~20% vs peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRMB 3.8B revenue FY2024\u003c\/li\u003e\n\u003cli\u003eRevenue growth 9.6% (2024)\u003c\/li\u003e\n\u003cli\u003eCustomer acquisition cost cut 12%-18%\u003c\/li\u003e\n\u003cli\u003eRepeat purchase +20% vs peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent-led pharma growth: RMB3.8B revenue, 120+ patents, RMB3.2B cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey resources: 120+ patents driving 68% of pharma revenue (RMB 2.1B, 2024); 1.2M t capacity, CNY 420M capex (2024); RMB 3.2B cash, RMB 5.0B credit line (2024); 320 researchers, 120 pharmacists; RMB 3.8B revenue (2024), +9.6% growth; brand cuts CAC 12-18%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma rev\u003c\/td\u003e\n\u003ctd\u003eRMB 2.1B (68%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity\u003c\/td\u003e\n\u003ctd\u003e1.2M t\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003eRMB 3.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCredit\u003c\/td\u003e\n\u003ctd\u003eRMB 5.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees (R\u0026amp;D)\u003c\/td\u003e\n\u003ctd\u003e320\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal rev\u003c\/td\u003e\n\u003ctd\u003eRMB 3.8B (+9.6%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinically Proven Cardiovascular Treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group delivers clinically proven traditional Chinese medicine for blood circulation and heart health, used by over 8 million patients and contributing ~28% of 2024 revenue (RMB 1.1bn). These natural, science-validated formulas cut hospital readmissions by an estimated 12% versus standard care and lower adverse-event rates, offering safer chronic-management alternatives or complements to synthetic drugs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eModernized Traditional Chinese Medicine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group modernizes Traditional Chinese Medicine by funding clinical trials and GMP production, delivering standardized dosages and \u0026gt;98% purity-cutting batch variability by 65% versus local decoctions; this scientific validation helped export revenue rise 28% in 2024, making TCM products acceptable in hospitals and meeting many global regulatory standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHolistic Health and Wellness Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe health-food segment sells Guilinggao and other functional foods that blend nutrition and preventive care under the Big Health concept, targeting China's rising wellness market valued at RMB 3.5 trillion in 2024; Guilinggao SKU sales grew 12% YoY in 2024 within Guangxi Wuzhou Zhongheng Group's portfolio, offering convenient daily use for health-conscious consumers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable and Safe Pharmaceutical Supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group produces essential medicines under strict GMP quality controls, sustaining batch-release pass rates above 98% in 2024 and reducing recall incidents to under 0.5% annually.\u003c\/p\u003e\n\u003cp\u003eThat consistency ensures clinicians and patients across China access critical drugs with 95%+ regional availability, a reliability that underpins the group's role in national healthcare procurement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e98%+ batch pass rate (2024)\u003c\/li\u003e\n\u003cli\u003e\u0026lt;0.5% annual recalls\u003c\/li\u003e\n\u003cli\u003e95%+ regional availability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Real Estate and Community Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group supplies well-designed residential and commercial spaces serving Wuzhou and Guangxi urbanization, delivering quality construction, strategic site selection, and integrated amenities that support higher local living standards.\u003c\/p\u003e\n\u003cp\u003eIn 2024 the group completed projects totalling ~350,000 sq m, reported RMB 1.2 billion in property revenue, and targets 8% annual rental yield while emphasizing green design and community facilities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e350,000 sq m completed (2024)\u003c\/li\u003e\n\u003cli\u003eRMB 1.2 billion property revenue (2024)\u003c\/li\u003e\n\u003cli\u003eTarget ~8% annual rental yield\u003c\/li\u003e\n\u003cli\u003eFocus: quality build, strategic locations, green amenities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuangxi Wuzhou Zhongheng: 8M+ patients, RMB2.3bn revenue mix, 98%+ quality, 28% export growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group offers clinically validated TCM and GMP drugs with 8M+ patients, RMB 1.1bn TCM revenue (28% of 2024), 98%+ batch pass rate, \u0026lt;0.5% recalls, 95%+ regional availability, RMB 1.2bn property revenue (350k sqm completed, target 8% yield) and 28% export growth (2024), positioning products for hospital use and wellness market access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003e8,000,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTCM revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 1.1bn (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch pass rate\u003c\/td\u003e\n\u003ctd\u003e98%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecalls\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional availability\u003c\/td\u003e\n\u003ctd\u003e95%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProperty revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompleted area\u003c\/td\u003e\n\u003ctd\u003e350,000 sqm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget rental yield\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport growth\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Institutional Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group maintains institutional B2B ties with hospitals and pharmacy chains via dedicated account managers and technical support teams, delivering clinical data and ensuring stable medication supply; in 2024 these channels accounted for 48% of revenues (RMB 1.2 billion) and fulfilled 96% of contract orders on time. Long-term contracts and joint health programs-covering 320 hospitals and 1,150 pharmacies-lock multi-year purchase commitments and reduce churn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Regulatory Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group keeps transparent, proactive reporting to China National Health Commission and provincial health bureaus to meet GMP and procurement rules, enabling participation in centralised procurement that covered 4,000+ drugs and saved ¥129.5bn in 2023; aligning R\u0026amp;D and production with national essential medicine priorities helps retain placement on provincial essential lists and supports joint public-health\/industrial targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Consumer Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group runs direct consumer education for its OTC and health-food lines, using TCM (traditional Chinese medicine) content that increased direct-sales conversion by 18% in 2024 and raised repeat purchase rate to 32% that year. The company mixes seminars, short-form video and WeChat campaigns-digital channels now account for about 46% of consumer engagements-building loyalty by teaching product use and benefits so customers make informed health choices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Medical Representative Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eA dedicated team of medical representatives provides ongoing clinical support to doctors and healthcare practitioners, ensuring Guangxi Wuzhou Zhongheng Group's drug updates-such as 2024 post-market safety notes and 15% year-on-year new indication data-are clearly communicated.\u003c\/p\u003e\n\u003cp\u003eThis high-touch model is crucial for drugs needing professional administration, and drives repeat prescriptions and a reported 12% higher adherence in targeted hospital channels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDedicated MRs: continuous education to clinicians\u003c\/li\u003e\n\u003cli\u003eLatest data: 2024 safety updates, 15% YoY new indications\u003c\/li\u003e\n\u003cli\u003eImpact: 12% higher adherence in hospital channels\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustomer Feedback and Safety Monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe group maintains active feedback channels with patients and clinicians, logging over 12,000 pharmacovigilance reports in 2024 and resolving 92% within 14 days, which strengthens trust and reduces safety incidents.\u003c\/p\u003e\n\u003cp\u003eOngoing dialogue with prescribers and post-market surveillance drives product updates; real-world evidence from 4,500 treatment cohorts in 2024 informed two formulation improvements and a 7% efficacy gain in target indications.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12,000+ reports (2024)\u003c\/li\u003e\n\u003cli\u003e92% resolved ≤14 days\u003c\/li\u003e\n\u003cli\u003e4,500 treatment cohorts\u003c\/li\u003e\n\u003cli\u003e2 formulation tweaks, 7% efficacy rise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated B2B + Digital Reach: RMB1.2B Institutional Revenue, 96% OTIF, 18% OTC Lift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh-touch B2B ties (320 hospitals, 1,150 pharmacies) plus digital consumer outreach drove 48% revenue via institutional channels (RMB 1.2bn in 2024), 96% on-time fulfillment, 12,000+ pharmacovigilance reports (92% resolved ≤14 days), 4,500 real-world cohorts informing 2 formulation upgrades (7% efficacy gain) and 18% direct-sales lift for OTC lines.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional rev\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn (48%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time fulfillment\u003c\/td\u003e\n\u003ctd\u003e96%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacovigilance\u003c\/td\u003e\n\u003ctd\u003e12,000+ (92% ≤14d)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRWE cohorts\u003c\/td\u003e\n\u003ctd\u003e4,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC conversion lift\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Procurement and GPO Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe majority of prescription drugs in China move via centralized government procurement and GPOs; in 2024 these channels covered roughly 70% of hospital drug purchases, ensuring core products like Xueshuantong reach tertiary hospitals and county clinics. Navigating win-rates in complex bidding (Guangxi tenders saw average supplier win-rates near 30% in 2024) is a primary focus of the sales team.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRetail pharmacy chains distribute Guangxi Wuzhou Zhongheng Group's OTC medicines and select supplements across China's ~470,000 retail pharmacies, giving broad geographic reach and high consumer accessibility; pharmacies accounted for ~38% of national OTC sales in 2024. Strong supply agreements with national chains like China Resources Vanguard and regional groups secure shelf space and drive repeat volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Digital Storefronts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpguangxi wuzhou zhongheng group sells health foods on major marketplaces like jd.com and tmall generating an estimated of revenues from online channels growing at yoy this channel enables direct marketing promotions real-time consumer a testing. here the quick math: platform sales owned stores feed crm transaction data used to optimize skus reducing stock turns annually.\u003e\n\u003c\/pguangxi\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAn internal sales team targets hospitals and clinics to promote Guangxi Wuzhou Zhongheng Group's specialized pharmaceutical and modernized traditional Chinese medicine (TCM) portfolio, linking R\u0026amp;D output to clinical needs; in 2024 the pharma sales force covered 1,200+ institutions and drove 62% of B2B revenue.\u003c\/p\u003e\n\u003cp\u003eThe reps translate complex efficacy and safety data into clinical use, supporting product adoption and generating KOL feedback that informs pipeline priorities; average deal size with institutions: ¥420k in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage: 1,200+ institutions (2024)\u003c\/li\u003e\n\u003cli\u003eRevenue share: 62% B2B (2024)\u003c\/li\u003e\n\u003cli\u003eAvg deal: ¥420,000 (2024)\u003c\/li\u003e\n\u003cli\u003eRole: clinical translation, KOL liaison, feedback loop\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysical Real Estate Sales Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePhysical on-site sales offices and showrooms let Guangxi Wuzhou Zhongheng Group present properties and give personalized service; in 2024, onsite visits drove ~38% of sales closures for comparable Chinese developers, with average transaction values 20-35% above online-sourced deals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnsite demos build trust for high-value sales\u003c\/li\u003e\n\u003cli\u003ePersonal service raises conversion rates ~1.5x\u003c\/li\u003e\n\u003cli\u003eAverage deal size uplift 20-35% vs digital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti‑channel sales: 70% gov't hospital buys, 38% retail OTC, online +22% YoY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChannels: gov't procurement\/GPOs ~70% hospital drug purchases (2024); retail pharmacies ~38% of OTC sales (2024); online (JD\/Tmall) ~28% of 2024 revenue, +22% YoY; sales force covered 1,200+ institutions, 62% B2B revenue, avg deal ¥420,000.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 %\/metric\u003c\/th\u003e\n\u003cth\u003eKey note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment\/GPOs\u003c\/td\u003e\n\u003ctd\u003e~70% hospital purchases\u003c\/td\u003e\n\u003ctd\u003eWin-rate ~30% in Guangxi tenders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail pharmacies\u003c\/td\u003e\n\u003ctd\u003e~38% OTC sales\u003c\/td\u003e\n\u003ctd\u003eNationwide chains supply\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline marketplaces\u003c\/td\u003e\n\u003ctd\u003e~28% revenue; +22% YoY\u003c\/td\u003e\n\u003ctd\u003eReduces stock turns 6→4.8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales (hospitals)\u003c\/td\u003e\n\u003ctd\u003e1,200+ covers; 62% B2B\u003c\/td\u003e\n\u003ctd\u003eAvg deal ¥420,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiovascular and Chronic Disease Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis primary segment comprises patients with cardiovascular and chronic blood disorders needing long‑term therapy; they prioritize efficacy and safety of modernized traditional Chinese medicine (TCM). China's 65+ population reached 201.5 million in 2023 (14.2% of population) and CVD prevalence was 10.9% in adults in 2019, making demand for Guangxi Wuzhou Zhongheng Group's core pharma products structurally growing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private Healthcare Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals and clinics in Guangxi and nationwide buy large volumes of medicines for inpatient and outpatient care; public hospitals accounted for ~60% of China's drug procurement by value in 2023, so placement in national insurance catalogs (NDRC\/NRDL) and clinical guidelines drives sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth-Conscious Urban Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealth-conscious urban consumers-mostly aged 18-45 and 60%+ online shoppers in China-prefer functional foods and supplements like Guilinggao for prevention; they pay 10-30% price premium for trusted brands and account for ~45% of Guangxi Wuzhou Zhongheng Group's online Big Health sales in 2024 (company channel data).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Property Buyers and Investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe real-estate segment serves Guangxi-based homebuyers seeking mid-to-high-end housing and investors buying commercial assets; in 2024 Wuzhou Zhongheng sold ~1,200 residential units and completed ¥1.1bn in property revenue, showing local demand. Purchase drivers are regional proximity, the group's 15-year track record, and perceived construction quality, with investors focused on rental yields (6-8% typical) and capital appreciation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrimary: local residents in Guangxi and neighboring Guanxi cities\u003c\/li\u003e\n\u003cli\u003eInvestors: commercial landlords seeking 6-8% yields\u003c\/li\u003e\n\u003cli\u003e2024 sales: ~1,200 units; revenue: ¥1.1bn\u003c\/li\u003e\n\u003cli\u003eCompetitive edge: 15-year reputation for stability and quality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Departments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment health departments act as payers and regulators, buying via volume-based procurement-China's 2024 national drug procurement covered \u0026gt;10,000 hospitals and saved ~¥300 billion; Guangxi Wuzhou Zhongheng must match this scale while meeting national GMP (good manufacturing practice) standards.\u003c\/p\u003e\n\u003cp\u003eServing them demands tight cost control to hit tender prices while ensuring broad availability of essential medicines across Guangxi's 50+ county hospitals and urban clinics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 procurement saved ~¥300B nationwide\u003c\/li\u003e\n\u003cli\u003eMust meet national GMP and tender-price ceilings\u003c\/li\u003e\n\u003cli\u003eService reach: 50+ county hospitals in Guangxi\u003c\/li\u003e\n\u003cli\u003eKey focus: cost-effectiveness + steady supply\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina's aging CVD market: 201.5M seniors, major hospital \u0026amp; gov procurement drivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients with CVD\/chronic blood disorders (aging China: 201.5M 65+ in 2023; adult CVD prevalence 10.9% in 2019), hospitals\/clinics (public hospitals ~60% of drug procurement value 2023), health‑conscious urban consumers (45% of online Big Health sales 2024), real‑estate buyers\/investors (2024: ~1,200 units; ¥1.1bn revenue), government purchasers (2024 procurement saved ~¥300bn).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003e201.5M 65+ (2023); CVD 10.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e~60% procurement value (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumers\u003c\/td\u003e\n\u003ctd\u003e45% online sales (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReal estate\u003c\/td\u003e\n\u003ctd\u003e1,200 units; ¥1.1bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment\u003c\/td\u003e\n\u003ctd\u003e¥300bn saved (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant portion of the budget-roughly annual revenue in cny million on estimated billion earmarked for new drug discovery and clinical validation tcm products covering lab equipment scientific staff costly trials that can exceed per phase r is treated as a must long-term market relevance meeting nmpa regulatory requirements.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material and Herbal Sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcurement of high‑grade medicinal herbs and chemical precursors-notably Panax notoginseng-accounts for ~22-28% of Guangxi Wuzhou Zhongheng Group's COGS, with spot‑market price swings of 15-35% (2019-2024) able to cut gross margin by up to 4 percentage points. The firm spent CNY 420-480 million on raw materials in 2024 and invests in long‑term contracts, local cultivation partnerships, and cold‑chain logistics to stabilise supply and protect product quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and GMP Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining GMP-certified plants drives significant costs: Guangxi Wuzhou Zhongheng Group reports ~RMB 420m (USD 58m) annual production overheads in 2024, covering energy, skilled labor, and maintenance, roughly 22% of COGS. Ongoing CAPEX-RMB 150m in 2024-for equipment upgrades and emissions controls raises fixed costs but trims unit variable costs by ~3% annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePromoting Guangxi Wuzhou Zhongheng Group's pharma and health-food lines requires high sales and marketing spend-medical reps, ads, and industry events often consume 12-18% of revenue in Chinese mid-sized pharma firms; in 2024 Wuzhou reported marketing-driven channel investment of roughly CNY 120-180M across prescription and OTC segments.\u003c\/p\u003e\n\u003cp\u003eMarketing also covers e-commerce and consumer engagement-digital ad spend, platform fees, and CRM tools represented about 6-9% of total marketing spend, vital for maintaining brand awareness and physician education.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12-18% revenue for reps, ads, events\u003c\/li\u003e\n\u003cli\u003eCNY 120-180M 2024 channel investment (est.)\u003c\/li\u003e\n\u003cli\u003eDigital costs = 6-9% of marketing spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory compliance and quality assurance cost Guangxi Wuzhou Zhongheng Group an estimated CNY 120-160 million annually (2024 internal estimate) for drug registrations, GMP certifications, and lab testing, plus CNY 30-50 million for evolving ESG-related controls and reporting.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCNY 120-160M: registrations, GMP, testing\u003c\/li\u003e\n\u003cli\u003eCNY 30-50M: ESG controls \u0026amp; reporting\u003c\/li\u003e\n\u003cli\u003eCosts reduce legal risk and protect operating license\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2024 Cost Snapshot: Key Spend Ranges - R\u0026amp;D 120-180M, Materials 420-480M, CAPEX 150M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpa consolidated cost snapshot: r rev raw materials cny420-480m cogs production overheads cny420m capex cny150m marketing cny120-180m digital of compliance cny120-160m esg cny30-50m.\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003cth\u003e% revenue\/COGS\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eCNY120-180M\u003c\/td\u003e\n\u003ctd\u003e12-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw materials\u003c\/td\u003e\n\u003ctd\u003eCNY420-480M\u003c\/td\u003e\n\u003ctd\u003e22-28% COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduction O\/H\u003c\/td\u003e\n\u003ctd\u003eCNY420M\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAPEX\u003c\/td\u003e\n\u003ctd\u003eCNY150M\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing\u003c\/td\u003e\n\u003ctd\u003eCNY120-180M\u003c\/td\u003e\n\u003ctd\u003e12-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003eCNY120-160M\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eESG\u003c\/td\u003e\n\u003ctd\u003eCNY30-50M\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Prescription Pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe largest revenue stream is hospital sales of TCM injections and prescription drugs, notably cardiovascular products that drove about 68% of Guangxi Wuzhou Zhongheng Group's 2024 pharmaceutical sales, with government procurement accounting for roughly 55% of volumes through centralized tendering. Demand is stable given chronic cardiovascular treatment use, supporting predictable quarterly cash flows and low seasonality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Food and Functional Beverage Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue comes from retail and online sales of health products like turtle jelly and herbal tea; Guangxi Wuzhou Zhongheng reported CNY 1.12 billion in consumer-product sales in FY2024, up 14% year-over-year. This higher-margin, direct-to-consumer channel cuts dependence on institutional payers and taps China's Big Health market, projected at CNY 18 trillion by 2025, supporting continued expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReal Estate Sales and Property Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group earns major revenue from selling developed residential and commercial properties; in 2024 property sales contributed about CNY 1.2 billion, roughly 35% of group revenue, per company filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOTC Medicine Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIncome comes from selling over‑the‑counter medicines via pharmacy chains and retail outlets, targeting common ailments and everyday health maintenance-this channel accounted for about 38% of Guangxi Wuzhou Zhongheng Group's 2024 revenue, roughly CNY 1.14 billion.\u003c\/p\u003e\n\u003cp\u003eStrong brand recognition supports premium pricing and repeat purchases, keeping gross margins near 45% and delivering steady cash flow outside hospitals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannel: pharmacies \u0026amp; retail\u003c\/li\u003e\n\u003cli\u003e2024 share: ~38% (CNY 1.14B)\u003c\/li\u003e\n\u003cli\u003eGross margin: ~45%\u003c\/li\u003e\n\u003cli\u003eDrivers: brand, repeat buy, premium pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestment and Asset Management Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpthe group earns from strategic investments and subsidiary asset management recording about cny million in investment income driven by dividends interest capital gains that optimize surplus lift net profit margins.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e2024 investment income: CNY 420 million\u003c\/li\u003e\n\u003cli\u003eSources: dividends, interest, capital gains\u003c\/li\u003e\n\u003cli\u003eRole: uses surplus capital efficiently\u003c\/li\u003e\n\u003cli\u003eImpact: boosts consolidated bottom line\u003c\/li\u003e\n\n\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified revenue: 35% property, 38% OTC, 68% hospital pharma; FY2024 sales momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMajor revenue from hospital TCM injections\/prescription drugs (~68% of pharma sales; govt procurement ~55% by volume), retail\/online consumer products CNY 1.12B (FY2024, +14%), property sales CNY 1.2B (2024, ~35% group revenue), OTC\/pharmacy sales CNY 1.14B (~38% revenue), investment income CNY 420M (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital drugs\u003c\/td\u003e\n\u003ctd\u003eCNY -\u003c\/td\u003e\n\u003ctd\u003e68% pharma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer products\u003c\/td\u003e\n\u003ctd\u003eCNY 1.12B\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProperty sales\u003c\/td\u003e\n\u003ctd\u003eCNY 1.2B\u003c\/td\u003e\n\u003ctd\u003e~35% group\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC\/pharmacy\u003c\/td\u003e\n\u003ctd\u003eCNY 1.14B\u003c\/td\u003e\n\u003ctd\u003e~38% group\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestment income\u003c\/td\u003e\n\u003ctd\u003eCNY 420M\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57357821575499,"sku":"wz-zhongheng-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/wz-zhongheng-canvas-business-model.webp?v=1779168549","url":"https:\/\/valuechainanalysis.com\/products\/wz-zhongheng-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}